Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar.

Fareed, Areeba; Inam, Nimrah; Faraz, Fatima.

Afiliación

Fareed A; Karachi Medical and Dental College, karachi, Pakistan.
Inam N; Department of Pediatrics, Agha Khan University Hospital Hospital Clinical Laboratories, karachi, Pakistan.
Faraz F; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.

Rare Tumors ; 15: 20363613231183785, 2023.

Article en En | MEDLINE | ID: mdl-37333047